E-drug: WHO and ARV access (cont'd)
-------------------------------------------------------------------------
Dear all,
Maija raises more 'sceptical' points. However, as pointed out by the
moderator earlier on, I see no need to elect to follow the sceptical
route, as tempting as it is. Many institutions (eg, UNICEF and WHO)
are addressing the issues raised by Maija, even if these issues are
not in the public forum. I therefore think it is misleading to suggest
that the interest only focuses on product pricing. Prioritising problem
solving is allowing institutions to address all areas affecting the
delivery of products and healthcare services to people suffering from
TB, malaria and HIV/AIDS. But, let's acknowledge that personnel and
other needs are being equally addressed. As with all things, it is a
question of how much financing (other resources, such as technical
support) is available to allow these problem areas to be addressed in
quick time. We may argue for centralising all these efforts, and so
make better use of expertise, resources, and reduce the time- lag to
providing an answer.
Regards,
Bonnie
Bonnie Fundafunda
Contracts Officer
UNICEF - Supply Division (Immunisation)
Copenhagen
Denmark
e-mail: bfundafunda@unicef.org
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug